Millennium 2Q Revenues: $120 million (+9%) 2Q Loss: $17.9 million (loss of $44 million in 2Q2005) YTD Revenues: $242.6 million (+4%) YTD Loss: $38.5 million (loss of $80 million YTD2005) Comments: U.S. Velcade sales increased 34% to $58.8 million in the quarter. Royalties associated with Integrilin Injection worldwide sales and Velcade ex-U.S. sales were $34.2 million for the quarter. Revenue from strategic alliances increased 42% to $27.2 million in the quarter. R&D ex...